WO WO9311161A1
· 1993
[cited by applicant]
WO WO9413804A1
· 1994
[cited by applicant]
WO WO9951642A1
· 1999
[cited by applicant]
WO WO2008068048A2
· 2008
[cited by examiner]
WO WO2011104604A2
· 2011
[cited by applicant]
WO WO2012131555A2
· 2012
[cited by applicant]
WO WO2012135345A1
· 2012
[cited by applicant]
WO WO2017180913A2
· 2017
[cited by applicant]
WO WO2020098672A1
· 2020
[cited by applicant]
WO WO2022058539A1
· 2022
[cited by applicant]
Kussie, Paul H., “A Single Engineered Amino Acid Substitution Changes Antibody Fine Specificity”, 1994, Journal of Immunology 152(1): pp. 146-152. (Year: 1994).
[cited by examiner]
Chen et al., Enhancement and destruction of antibody function by somatic mutation: unequal occurrence is controlled by V gene combinatorial associations. EMBO J. Jun. 15, 1995;14(12):2784-94. (Year: 1995).
[cited by examiner]
Chao et al. “The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications”, 2012, Current Opinion in Immunology: 24(2): pp. 225-232. (Year: 2012).
[cited by examiner]
Zuch de Zafra et al. “Targeting multiple myeloma with AMG 424, a novel anti-CD38/CD3 bispecific T-cell-recruiting antibody optimized for cytotoxicity and cytokine release”, 2019, Clinical Cancer Research: 25: pp. 3921-3…
[cited by examiner]
Edwards et al., The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS. J Mol Biol. Nov. 14, 2003;334(1):103-18. (Year: 2003).
[cited by examiner]
Koenig et al., Mutational landscape of antibody variable domains reveals a switch modulating the interdomain conformational dynamics and antigen binding. PNAS Jan. 24, 2017 114 (4) E486-E495; first published Jan. 5, 201…
[cited by examiner]
Anderson, K.C., et al., “Clinically Relevant End Points and New Drug Approvals for Myeloma,” Leukemia, 22(2):231-239, Nature Publishing Group, England (Feb. 2008).
[cited by applicant]
Bird, R.E., et al., “Single-chain Antigen-binding Proteins,” Science 242(4877):423-426, Association for the Advancement of Science, United States (Oct. 1988).
[cited by applicant]
Bluemel, C., et al., “Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen,” Cancer Immunol Immuno…
[cited by applicant]
Bommel, P.E.V., et al., “CD20-selective Inhibition of CD47-SIRPα “Don't Eat Me” Signaling With a Bispecific Antibody-Derivative Enhances the Anticancer Activity of Daratumumab, Alemtuzumab, and Obinutuzumab,” Oncoimmuno…
[cited by applicant]
Chao, M.P., et al., “Anti-CD47 Antibody Synergizes With Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma,” Cell, 142(5):699-713, Cell Press, United States (Sep. 2010).
[cited by applicant]
Chothia, C. and Lesk, A.M., “Canonical Structures for the Hypervariable Regions of Immunoglobulins,” Journal of Molecular Biology 196(4):901-917, Elsevier, England (Aug. 1987).
[cited by applicant]
Chothia, C., et al., “Conformations of Immunoglobulin Hypervariable Regions,” Nature 342(6252):877-883, Nature Publishing Group, England (Dec. 1989).
[cited by applicant]
Coloma, M.J. and Morrison, S.L., “Design and Production of Novel Tetravalent Bispecific Antibodies,” Nature Biotechnology 15(2):159-163, Nature America Publishing, United States (Feb. 1997).
[cited by applicant]
Frankel, S.R., et al., “Targeting T Cells to Tumor Cells using Bispecific Antibodies,” Current Opinion in Chemical Biology 17(3) 385-92, Elsevier, England (Jun. 2013).
[cited by applicant]
Hinton, P.R., et al., “An Engineered Human IgG1 Antibody with Longer Serum Half-Life,” Journal of Immunology 176(1):346-356, American Association of Immunologists, United States (2006).
[cited by applicant]
Holliger, P., et al., “Diabodies: Small Bivalent and Bispecific Antibody Fragments,” Proceedings of the National Academy of Sciences of the United States of America 90(14):6444-6448, National Academy of Sciences, United…
[cited by applicant]
Huston, J.S., et al., “Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-digoxin Single-chain Fv Analogue Produced in
[cited by applicant]
Kabat, E.A. et al., Sequences of Proteins of Immunological Interest, Fifth Edition, vol. 1, pp. iii-xi, 103, 310, U.S. Department of Health and Human Services, Public Health Services, National Institute of Health, NIH P…
[cited by applicant]
Kalim, M., et al., “Intracellular Trafficking of New Anticancer Therapeutics Antibody drug Conjugates,” Drug Design, Development and Therapy 11:2265-2276, Dove Press Limited, New Zealand (Aug. 2017).
[cited by applicant]
Lazar, G.A., et al., “Engineered Antibody Fc Variants with Enhanced Effector Function,” Proceedings of the National Academy of Sciences USA 103(11):4005-4010, National Academy of Sciences, United States (2006).
[cited by applicant]
Lefranc, M.P., et al., “Imgt Unique Numbering for Immunoglobulin and T Cell Receptor Variable Domains and Ig Superfamily V like Domains,” Developmental and Comparative Immunology 27(1) 55-77, Elsevier Science, United St…
[cited by applicant]
MacCallum, R.M., et al., “Antibody-antigen Interactions: Contact Analysis and Binding Site Topography,” Journal of Molecular Biology 262(5):732-745, Academic Press, England (Oct. 1996).
[cited by applicant]
Martin, A.C.R., “Protein Sequence and Structure Analysis of Antibody Variable Domains,” Chapter 3 in Antibody Engineering, vol. 2, Second Edition, pp. 33-51, Roland Kontermann and Stefan Dübel (eds), Springer-Verlag Ber…
[cited by applicant]
Martin, W.L., et al., “Crystal Structure at 2.8 A of an FcRn/Heterodimeric Fc Complex: Mechanism of pH-Dependent Binding,” Molecular Cell 7(4):867-877, Cell Press, United States (2001).
[cited by applicant]
Masui, S., et al., “An Efficient System to Establish Multiple Embryonic Stem Cell Lines Carrying an Inducible Expression Unit,” Nucleic Acids Research 33(4) e43, Oxford University Press, England (Mar. 2005).
[cited by applicant]
May, C., et al., “Advances in Bispecific Biotherapeutics for the Treatment of Cancer,” Biochemical Pharmacology 84(9):1105-1112, Elsevier Science, England (Nov. 2012).
[cited by applicant]
Nie, S., et al., “Biology Drives the Discovery of Bispecific Antibodies as Innovative Therapeutics,” Antibody Therapeutics 3(1):18-62, Oxford University Press, United States (Feb. 2020).
[cited by applicant]
Niwa, H., et al., “Efficient Selection for High-Expression Transfectants With a Novel Eukaryotic Vector,” Gene 108(2) 193-9, Elsevier/North-Holland, Netherlands (Dec. 1991).
[cited by applicant]
Ollier, R., et al., “Single-Step Protein A and Protein G Avidity Purification Methods to Support Bispecific Antibody Discovery and Development,” mAbs 11(8):1464-1478, Taylor and Francis, United States (Dec. 2019).
[cited by applicant]
Padlan, E.A., et al., “Identification of Specificity-Determining Residues in Antibodies,” FASEB Journal 9(1):133-139, Federation of American Societies for Experimental Biology, United States (Jan. 1995).
[cited by applicant]
Parslow, A.C., et al., “Antibody-Drug Conjugates for Cancer Therapy,” Biomedicines 4(3):14, MDPI AG, Switzerland (Jul. 2016).
[cited by applicant]
Richards, J.O., et al, “Optimization of Antibody Binding to FcgammaRlla Enhances Macrophage Phagocytosis of Tumor Cells,” Molecular Cancer Therapeutics 7(8):2517-2527, American Association for Cancer Research, United St…
[cited by applicant]
Scott, J.L., et al., “Characterization of a Novel Membrane Glycoprotein Involved in Platelet Activation,” The Journal of Biological Chemistry 264(23):13475-13482, Elsevier Inc, United States (Aug. 1989).
[cited by applicant]
Shields, R.L., et al., “High Resolution Mapping of the Binding Site on Human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIll, and FcRn and Design of IgG1 Variants with Improved Binding to the Fc gamma R,” The Journal …
[cited by applicant]
Sikic, B.I., et al., “First-in-human, First-in-class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers,” Journal of Clinical Oncology 37(12):946-953, American Society of Clinical Oncolog…
[cited by applicant]
Skegro, D., et al., “Immunoglobulin Domain Interface Exchange as a Platform Technology for the Generation of Fc Heterodimers and Bispecific Antibodies,” The Journal of Biological Chemistry 292(23) 9745-9759, Elsevier, U…
[cited by applicant]
Smith, E.J., et al., “A Novel, Native-Format Bispecific Antibody Triggering T-Cell Killing of B-cells is Robustly Active in Mouse Tumor Models and Cynomolgus Monkeys,” Scientific Reports 5:17943, Nature Publishing Group…
[cited by applicant]
Sondergeld, P., et al., “Monoclonal Antibodies in Myeloma,” Clinical Advances in Hematology and Oncology 13(9):599-609, Millennium Medical Pub, United States (Sep. 2015).
[cited by applicant]
Sonneveld, P. and Broijl, A., “Treatment of Relapsed and Refractory Multiple Myeloma,” Haematologica 101(4):396-406, Ferrata Storti Foundation, Italy (Apr. 2016).
[cited by applicant]
Stutz, C. and Blein, S., “A Single Mutation Increases Heavy-chain Heterodimer Assembly of Bispecific Antibodies by Inducing Structural Disorder in One Homodimer Species,” The Journal of Biological Chemistry 295(28):9392…
[cited by applicant]
Tai, Y., et al., “Anti-CS1 Humanized Monoclonal Antibody Huluc63 Inhibits Myeloma Cell Adhesion and Induces Antibody-dependent Cellular Cytotoxicity in the Bone Marrow Milieu,” Blood 112(4):1329-1337, Elsevier, United S…
[cited by applicant]
Tandon, N., et al., “Monoclonal Antibodies for the Treatment of Multiple Myeloma—A New Paradigm,” Oncology & Hematology Review 11(2):115-121 (2015).
[cited by applicant]
Thompson, J.D., et al., “Clustal W: Improving the Sensitivity of Progressive Multiple Sequence Alignment through Sequence Weighting, Position-specific Gap Penalties and Weight Matrix Choice,” Nucleic Acids Research 22(2…
[cited by applicant]
Tomlinson, I. and Holliger, P., “[28] Methods for Generating Multivalent and Bispecific Antibody Fragments,” Methods in Enzymology 326:461-479, Academic Press, United States (2000).
[cited by applicant]
Vogiatzi, F., et al., “Co-Targeting of CD38 and CD47 in T Cell Acute Lymphoblastic Leukemia,” Blood 136(Supplement 1):39-40, ASH Publications, United States (Nov. 2020).
[cited by applicant]
Ward, E.S., et al., “Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted from
[cited by applicant]
Willingham, S.B., et al., “The CD47-Signal Regulatory Protein Alpha (SIRPa) Interaction is a Therapeutic Target for Human Solid Tumors,” Proceedings of the National Academy of Sciences of the United States of America 10…
[cited by applicant]
Yu, T., et al., “Novel Anti-CD38 Humanized mAb SG003 Possessed Enhanced Cytotoxicity in Lymphoma Than Daratumumab via Antibody-dependent Cell-mediated Cytotoxicity,” BMC Biotechnology 19(1):28, BioMed Central, England (…
[cited by applicant]
Boyd-Kirkup, J., et al., “HMBD004, a Novel Anti-CD47xCD33 Bispecific Antibody Displays Potent Anti-Tumor Effects in Pre-Clinical Models of AML,” Blood 130(1):1378, American Society of Hematology, United States (2017).
[cited by applicant]
Demichelis-Gomez, R., et al., “Bispecific Antibodies in Hematologic Malignancies: When, to Whom, and How Should Be Best Used?” Curr. Oncol. Rep. 21(2):17, Current Science, Inc., United States (Feb. 2019).
[cited by applicant]
Dheilly, E., et al., “Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies,” Mol. Ther. 25(2):523-533, Cell Press, United States (2017).
[cited by applicant]
Ferrero, E., et al., “Characterization and phylogenetic epitope mapping of CD38 Adpr cyclase in the cynomolgus macaque,” BMC Immunol. 5(1):21, BioMed Central, United Kingdom (2004).
[cited by applicant]
Guy, D.G., et al., “Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia,” Curr. Hematol. Malig. Rep. 13(6):417-425, Springer Science + Business Media, United States (Oct. 2018).
[cited by applicant]
Labrijn, A.F., et al., “Bispecific antibodies: a mechanistic review of the pipeline,” Nat. Rev. Drug Discov. 18(8):585-608, Nature Publishing Group, Germany (Jun. 2019).
[cited by applicant]
Li., H., et al., “Highlights of 2019 Protein Engineering Summit (PEGS) in Boston, USA: Advancing Antibody-Based Cancer Therapies to the Clinic,” Antib. Ther. 2(4):79-87, Oxford Academic Press, United Kingdom (Sep. 2019).
[cited by applicant]
Moore, G.L., et al., “A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats,” Methods 154:38-50, Elsevier, Netherlands (Feb. 2019).
[cited by applicant]
Piccione, E.C., et al., “A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells,” MAbs. 7(5):946-956, Taylor & Francis, United Kingdom (2015).
[cited by applicant]
Sun, J., et al., “Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma,” Cancers 12(2):305, MDPI, Switzerland (Jan. 2020).
[cited by applicant]
Suurs, F.V., et al., “A review of bispecific antibodies and antibody constructs in oncology and clinical challenges,” Pharmacol. Therap. 201:103-119, Elsevier, Netherlands (Apr. 2019).
[cited by applicant]
Van De Donk, N.W., et al., “CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance,” Front. Immunol. 9:2134, Frontiers Media S.A., Switzerland (Sep. 2018).
[cited by applicant]
Zuch De Zafra, C.L., et al., “Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release,” Clin. Cancer Res. 25(13):3921-3933, Am…
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/EP2021/075687, mailed Jan. 4, 2022, European Patent Office, Netherlands, 23 pages.
[cited by applicant]